{"id":2461,"date":"2026-08-30T08:47:02","date_gmt":"2026-08-30T08:47:02","guid":{"rendered":"https:\/\/one-peptides.com\/?p=2461"},"modified":"2026-08-30T19:55:46","modified_gmt":"2026-08-30T19:55:46","slug":"cardarine-vs-ostarine-mk-2866-what-the-research-says","status":"publish","type":"post","link":"https:\/\/one-peptides.com\/es\/cardarine-vs-ostarine-mk-2866-what-the-research-says\/","title":{"rendered":"Cardarine vs Ostarine (MK-2866) \u2014 What Does the Research Say?"},"content":{"rendered":"

In brief.<\/strong> Cardarine and ostarine often appear next to one another in catalogues, but they belong to two distinct pharmacological classes<\/strong>. Cardarine (GW-501516)<\/strong> is a PPAR\u03b4 nuclear receptor agonist; it does not bind the androgen receptor and is not a SARM<\/strong>. Its clinical development was halted after long-term rodent studies reported tumours in multiple organs. Ostarine (MK-2866, enobosarm)<\/strong> is a selective androgen receptor modulator<\/strong> with the broadest human evidence base in its class; a 12-week phase 2 study in healthy older adults reported an increase in lean body mass. Both compounds appear on the WADA Prohibited List, and neither is approved as a medicine. In commerce they function solely as research reagents (Research Use Only)<\/a>.<\/em><\/p>\n

This educational article reviews published scientific literature. Reported effects refer to the cell, animal or clinical models specified in the cited studies and are not promises of outcomes in readers. This text is not medical or dietary advice. One Peptides catalogue compounds are intended solely for laboratory research (RUO) and are neither medicines nor dietary supplements.<\/p>\n

What is the difference between cardarine and ostarine?<\/h2>\n

The shortest answer is: they act through different receptors and therefore through different biology. Cardarine acts on the nuclear receptor PPAR\u03b4, which regulates fatty-acid metabolism. Ostarine acts on the androgen receptor, which regulates muscle and bone tissue. They are not two versions of the same approach; they are two separate signaling systems that happen to appear beside one another in catalogues.<\/p>\n

The comparison comes from commercial practice, not pharmacology. Cardarine is often described as a SARM in price lists and online discussions, but that classification is incorrect because it has no affinity for the androgen receptor. The table below organizes the differences discussed in the following sections.<\/p>\n

Table: cardarine vs ostarine at a glance<\/h3>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Feature<\/th>\nCardarine (GW-501516)<\/th>\nOstarine (MK-2866, enobosarm)<\/th>\n<\/tr>\n
Pharmacological class<\/th>\nPPAR\u03b4 nuclear receptor agonist<\/td>\nSelective androgen receptor modulator (SARM)<\/td>\n<\/tr>\n
Target receptor<\/th>\nPPAR\u03b4 (PPAR\u03b2\/\u03b4)<\/td>\nAndrogen receptor (AR)<\/td>\n<\/tr>\n
Is it a SARM?<\/th>\nNo<\/td>\nYes<\/td>\n<\/tr>\n
Developing organization<\/th>\nGlaxoSmithKline<\/td>\nGTx Inc.<\/td>\n<\/tr>\n
Research area<\/th>\nLipid metabolism and aerobic capacity<\/td>\nLean body mass and cancer cachexia<\/td>\n<\/tr>\n
Longest human study<\/th>\nDevelopment halted at an early stage<\/td>\n16 weeks<\/td>\n<\/tr>\n
Safety signal in the literature<\/th>\nTumours in long-term rodent studies<\/td>\nLiver injury in case reports<\/td>\n<\/tr>\n
WADA status<\/th>\nProhibited \u2014 S4 metabolic modulators<\/td>\nProhibited \u2014 S1 anabolic agents<\/td>\n<\/tr>\n
Approved as a medicine<\/th>\nNo<\/td>\nNo<\/td>\n<\/tr>\n
Commercial status<\/th>\nResearch reagent (RUO)<\/td>\nResearch reagent (RUO)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

How does cardarine (GW-501516) work?<\/h2>\n

Cardarine is an agonist of PPAR\u03b4<\/strong>, a transcription factor in the peroxisome proliferator-activated receptor family. This receptor regulates the expression of genes involved in fatty-acid oxidation, and its activation shifts cellular metabolism toward greater use of lipids as an energy source.<\/p>\n

The study that characterized the compound reported that GW-501516 promoted reverse cholesterol transport and increased HDL cholesterol in animal models (Oliver et al., 2001). Subsequent work in skeletal-muscle cells described regulation of genes involved in lipid catabolism and energy uncoupling (Dressel et al., 2003). The most widely cited paper in this area compared PPAR\u03b4 agonists with AMPK activators and described both mechanisms as exercise mimetics, meaning compounds that activate a muscle transcriptional programme resembling part of the response to endurance training (Narkar et al., 2008). The boundary of that observation is important: it was reported in an animal model and concerned a transcriptional programme, not a replacement for exercise.<\/p>\n

Clinical development of cardarine was discontinued in 2007<\/strong>. The decision followed long-term toxicology studies in rodents in which tumours developed in multiple organs. These data were not published as a standalone peer-reviewed paper; they came from the preclinical documentation of the compound’s developer and were communicated publicly by the World Anti-Doping Agency. That publication gap is itself relevant: there is no peer-reviewed clinical paper that overturns or materially qualifies this signal<\/strong>. A separate review explains what cardarine is and how it acts at PPAR\u03b4<\/a>.<\/p>\n

How does ostarine (MK-2866) work?<\/h2>\n

Ostarine, also known as enobosarm and GTx-024, is a nonsteroidal selective androgen receptor modulator<\/strong>. It binds the same receptor as testosterone, but as a nonsteroidal compound it does not undergo the same metabolic conversions and produces a different distribution of activity across tissues. Mechanistic studies indicate that compounds in this class activate canonical androgen-receptor signaling, while differences in their profiles result from tissue-specific recruitment of coregulatory proteins (Nyquist et al., 2021). Narayanan and colleagues (2018) reviewed the development history and design principles of the entire class.<\/p>\n

Ostarine stands out within its class because of the breadth of its human research. In a 12-week randomized phase 2 trial involving healthy older men and postmenopausal women, researchers reported an increase in lean body mass and an improvement in a physical-function test versus placebo (Dalton et al., 2011). A separate programme addressed cancer-associated muscle wasting; a study published in Lancet Oncology<\/em> evaluated enobosarm’s effects on muscle mass and physical function in people with cancer (Dobs et al., 2013).<\/p>\n

An important interpretive limitation is the time horizon: the longest published clinical trials of ostarine lasted 16 weeks<\/strong>. Anything that may occur with longer exposure lies outside the published evidence. Despite having the broadest documentation in its class, ostarine did not complete a regulatory approval pathway<\/strong> and is not registered as a medicine in any jurisdiction. A dedicated article reviews the clinical research status of ostarine<\/a>, while research variants are grouped in the MK-2866 category<\/a>.<\/p>\n

Why is cardarine not a SARM?<\/h2>\n

This is the most common classification error involving this pair and should be resolved directly. A SARM is a compound that binds the androgen receptor. Cardarine does not bind that receptor; it acts on PPAR\u03b4, a receptor from a different family that regulates lipid metabolism rather than androgen signaling.<\/p>\n

The distinction has practical consequences for interpreting the literature. Ostarine studies measure endpoints related to muscle tissue and androgen-receptor activity. Cardarine studies measure parameters related to lipid metabolism and aerobic performance. There is no basis for transferring conclusions between these two datasets; they are separate bodies of literature describing separate biological systems.<\/p>\n

The confusion arises from commercial classification: cardarine appears in the same price lists as SARMs and is sometimes labelled as one by sellers. The catalogue keeps the cardarine category<\/a> separate from the SARM category<\/a> to preserve that pharmacological distinction.<\/p>\n

What is known about the safety of both compounds?<\/h2>\n

This comparison is especially important because the literature contains documented safety signals for both compounds, although the signals differ in type and evidential strength.<\/p>\n

Cardarine: an oncological signal in animal models.<\/strong> Long-term toxicology studies in rodents found tumour development in multiple organs, which led to termination of the development programme in 2007. This is the single most serious fact associated with the compound, and no subsequent study has overturned it. In 2013, the World Anti-Doping Agency issued a public warning about the health risk associated with GW-501516.<\/p>\n

Ostarine: hepatic signals in case reports.<\/strong> The clinical literature includes reports of liver injury in people who used products labelled as containing SARMs. A case report, however, provides much weaker evidence than a randomized trial.<\/p>\n

A case involving both compounds.<\/strong> A separate paper described a 43-year-old man who presented to an emergency department after combined exposure to GW-501516 and MK-2866. Markedly elevated liver aminotransferases and severe rhabdomyolysis with very high creatine kinase activity were recorded, and both compounds were analytically confirmed in blood (Kintz et al., 2021). This is the only published clinical report concerning this exact combination.<\/p>\n

The safety picture also includes the problem of material identity<\/strong>. An analysis of products sold online as SARMs found that many did not contain the declared substance, contained a quantity inconsistent with the label, or included undeclared compounds (Van Wagoner et al., 2017). This illustrates why analytical documentation matters in laboratory work: chromatographic purity of at least 98%, identity confirmation by mass spectrometry and a batch-specific certificate of analysis, as provided for the GW-501516 research reagent<\/a> and the MK-2866 research reagent<\/a>.<\/p>\n

What is the anti-doping status of cardarine and ostarine?<\/h2>\n

Both compounds are prohibited in sport at all times<\/strong>, but they appear in different sections of the World Anti-Doping Agency Prohibited List.<\/p>\n

Cardarine is listed in category S4: Hormone and Metabolic Modulators<\/strong>. It was prohibited in 2009 because of its potential to artificially enhance endurance performance, and anti-doping laboratories have validated methods for detecting the compound and its metabolites (Thevis et al., 2013).<\/p>\n

Ostarine is listed in category S1: Anabolic Agents<\/strong> as a selective androgen receptor modulator. It is among the compounds from this class most frequently detected in anti-doping controls.<\/p>\n

The practical consequence is the same for both: an athlete subject to anti-doping rules may not use either compound, and both can be detected by routine analytical methods.<\/p>\n

Frequently Asked Questions<\/h2>\n

Is cardarine a SARM?<\/strong> No. Cardarine (GW-501516) is a PPAR\u03b4 nuclear receptor agonist and does not bind the androgen receptor. SARMs, including ostarine, act through the androgen receptor.<\/p>\n

What is the main difference between cardarine and ostarine?<\/strong> They target different receptors and therefore different biological pathways. Cardarine activates PPAR\u03b4 and has been studied in lipid metabolism and aerobic-capacity models. Ostarine modulates the androgen receptor and has been studied in relation to lean body mass and cancer cachexia.<\/p>\n

Which compound has been studied more extensively in humans?<\/strong> Ostarine has completed phase 2 human trials, including studies in cancer populations. Cardarine did not complete clinical development. This does not mean ostarine is approved or that its long-term safety has been established.<\/p>\n

Why was cardarine development halted?<\/strong> Long-term toxicology studies in rodents reported tumours in multiple organs. The programme was discontinued in 2007, and no later clinical programme has resolved that safety signal.<\/p>\n

Are both compounds prohibited in sport?<\/strong> Yes, at all times. Cardarine appears in category S4 of the WADA Prohibited List as a metabolic modulator, while ostarine appears in category S1 as an anabolic agent.<\/p>\n

Is either compound a medicine or dietary supplement?<\/strong> No. Neither cardarine nor ostarine is approved as a medicine in the European Union, the United States or another major jurisdiction, and neither is an authorized dietary-supplement ingredient. Here they are supplied solely as Research Use Only reagents.<\/p>\n

What is known about combining cardarine and ostarine?<\/strong> A case report described marked liver injury and severe rhabdomyolysis after combined exposure to GW-501516 and MK-2866, with both compounds analytically confirmed in blood (Kintz et al., 2021). This is a single case report, but it concerns this exact combination.<\/p>\n

Conclusion \u2014 two classes, not two variants<\/h2>\n

Cardarine and ostarine are compared because they appear beside one another in catalogues, not because their pharmacology is similar. Cardarine is a PPAR\u03b4 agonist whose clinical development was terminated after an unresolved oncological signal in animal models. Ostarine is an androgen receptor modulator with the broadest clinical documentation in its class, although that evidence extends only to 16 weeks and did not lead to regulatory approval. Both are prohibited in sport and remain available solely as research reagents.<\/p>\n

For anyone assessing the literature, the practical conclusion is straightforward: these are two separate bodies of evidence describing two separate receptors, and findings from one cannot be transferred to the other.<\/p>\n

RUO disclaimer.<\/strong> Cardarine (GW-501516) and ostarine (MK-2866) in the One Peptides catalogue are chemical reagents intended solely for laboratory and scientific research (Research Use Only). They are not medicines, dietary supplements or products intended for consumption or administration to humans or animals outside a controlled experimental setting. All effects described are findings reported in the cited studies and models, not claims of efficacy or indications for use. This information is educational and scientific and is not medical, pharmaceutical or dietary advice. Both compounds appear on the World Anti-Doping Agency Prohibited List.<\/em><\/p>\n

References<\/h2>\n
    \n
  1. Oliver WR Jr, Shenk JL, Snaith MR et al. (2001). A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport<\/cite><\/a><\/li>\n
  2. Dressel U, Allen TL, Pippal JB et al. (2003). The peroxisome proliferator-activated receptor beta\/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells<\/cite><\/a><\/li>\n
  3. Narkar VA, Downes M, Yu RT et al. (2008). AMPK and PPAR\u03b4 agonists are exercise mimetics<\/cite><\/a><\/li>\n
  4. Dalton JT, Barnette KG, Bohl CE et al. (2011). The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial<\/cite><\/a><\/li>\n
  5. Dobs AS, Boccia RV, Croot CC et al. (2013). Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial<\/cite><\/a><\/li>\n
  6. Nyquist MD, Ang LS, Corella A et al. (2021). Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth<\/cite><\/a><\/li>\n
  7. Narayanan R, Coss CC, Dalton JT (2018). Development of selective androgen receptor modulators (SARMs)<\/cite><\/a><\/li>\n
  8. Kintz P, Gheddar L, Paradis C et al. (2021). Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR-\u03b4) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine)<\/cite><\/a><\/li>\n
  9. Van Wagoner RM, Eichner A, Bhasin S et al. (2017). Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet<\/cite><\/a><\/li>\n
  10. Thevis M, M\u00f6ller I, Thomas A, Sch\u00e4nzer W (2013). Synthesis, mass spectrometric characterization, and analysis of the PPAR\u03b4 agonist GW1516 and its major human metabolites<\/cite><\/a><\/li>\n<\/ol>\n

    Regulatory sources: World Anti-Doping Agency, Prohibited List (cardarine: category S4, Hormone and Metabolic Modulators; ostarine: category S1, Anabolic Agents): WADA Prohibited List<\/a>. See also the WADA public warning issued in 2013 concerning the health risks of GW-501516.<\/em><\/p>\n